Skip to main content

thebench.bio #1 Ecosystem for the Bio-Tech Industry

News
Layoff Tracker
Events
Roles
Interview Questions

Industry news / Past summaries

Industry Daily Summary

Industry Daily Summary: What Happened on October 25, 2026

GlobalData analysts project $540 million in Mo-Rez sales by 2032

The forecast covers annual global sales of GSK’s ovarian cancer drug.

Updated October 26, 00:03 UTC
Read from 1 article, 1 publication

Today in brief

GlobalData’s consensus puts GSK’s Mo-Rez at $540 million in annual global sales in 2032.1

Sources

Source 1: Pharmaceutical Technology ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer https://www.pharmaceutical-technology.com/analyst-comment/esmo26-gsks-mo-rez-seeks-an-edge-in-a-crowded-adc-field-in-ovarian-cancer/

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

The day in numbers

$540 million

Projected annual global sales for Mo-Rez by 2032, according to GlobalData’s analyst consensus. 1

In this summary

Today in brief
Sources

Earlier: October 24

Explore

All news Daily summaries Layoff tracker Biotech events Roles explained Interview questions

Company

About Brand kit Stats

TheBench.Bio